DENTSPLY SIRONA Inc. $XRAY Stock Holdings Decreased by Amundi

Key Points

• Amundi cut its DENTSPLY SIRONA stake by 85.6% in the second quarter, selling 240,120 shares and retaining 40,344 shares valued at approximately $428,000.
• Institutional investors own approximately 95.7% of XRAY’s outstanding stock, with several other funds initiating or increasing positions during the reported periods.
• Analysts have a consensus “Hold” rating and an average price target of $13.54. DENTSPLY SIRONA beat quarterly EPS and revenue estimates, although revenue declined 4.1% year over year and the company reported a negative net margin.

Amundi lowered its position in shares of DENTSPLY SIRONA Inc. (NASDAQ:XRAY - Free Report) by 85.6% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 40,344 shares of the medical instruments supplier's stock after selling 240,120 shares during the quarter. Amundi's holdings in DENTSPLY SIRONA were worth $428,000 as of its most recent SEC filing.

Other hedge funds have also made changes to their positions in the company. Eurizon Capital SGR S.p.A. purchased a new position in DENTSPLY SIRONA during the 4th quarter worth approximately $26,000. Nykredit A S purchased a new stake in shares of DENTSPLY SIRONA in the second quarter valued at $38,000. Performa Ltd US LLC boosted its position in shares of DENTSPLY SIRONA by 116.1% in the fourth quarter. Performa Ltd US LLC now owns 4,250 shares of the medical instruments supplier's stock worth $49,000 after buying an additional 2,283 shares during the period. Huntington National Bank boosted its position in shares of DENTSPLY SIRONA by 68.3% in the fourth quarter. Huntington National Bank now owns 4,689 shares of the medical instruments supplier's stock worth $54,000 after buying an additional 1,903 shares during the period. Finally, Allworth Financial LP purchased a new position in shares of DENTSPLY SIRONA during the second quarter valued at $51,000. Hedge funds and other institutional investors own 95.70% of the company's stock.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on the company. BMO Capital Markets reissued a "market perform" rating and set a $13.00 price target on shares of DENTSPLY SIRONA in a research report on Friday, August 7th. Barclays raised their price objective on DENTSPLY SIRONA from $9.00 to $11.00 and gave the stock an "underweight" rating in a research report on Monday, August 24th. Piper Sandler upped their target price on DENTSPLY SIRONA from $13.00 to $14.00 and gave the company a "neutral" rating in a report on Wednesday, July 29th. Weiss Ratings reissued a "sell (e+)" rating on shares of DENTSPLY SIRONA in a research report on Monday, August 3rd. Finally, Barrington Research set a $15.00 price target on shares of DENTSPLY SIRONA in a report on Monday, August 10th. Three analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and three have issued a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus target price of $13.54.

DENTSPLY SIRONA Stock Performance

Shares of XRAY stock opened at $10.14 on Thursday. DENTSPLY SIRONA Inc. has a fifty-two week low of $9.40 and a fifty-two week high of $14.76. The stock's 50-day moving average is $12.01 and its two-hundred day moving average is $11.54. The company has a debt-to-equity ratio of 1.48, a current ratio of 1.63 and a quick ratio of 1.07. The firm has a market cap of $2.02 billion, a P/E ratio of -3.69, a PEG ratio of 1.25 and a beta of 0.84.

DENTSPLY SIRONA (NASDAQ:XRAY - Get Free Report) last announced its quarterly earnings results on Thursday, August 6th. The medical instruments supplier reported $0.52 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.35 by $0.17. The business had revenue of $898.00 million during the quarter, compared to analyst estimates of $889.93 million. DENTSPLY SIRONA had a positive return on equity of 20.84% and a negative net margin of 14.99%.The firm's revenue was down 4.1% on a year-over-year basis. During the same period in the previous year, the company earned $0.52 EPS. DENTSPLY SIRONA has set its FY 2026 guidance at 1.400-1.500 EPS. Analysts predict that DENTSPLY SIRONA Inc. will post 1.4 earnings per share for the current fiscal year.

About DENTSPLY SIRONA

DENTSPLY SIRONA is a global manufacturer of professional dental products and technologies. The company serves dentists, dental laboratories, and other oral health professionals with solutions spanning preventive, restorative, endodontic, orthodontic, implant, and prosthetic dentistry.

Its portfolio includes dental consumables, equipment and treatment centers, imaging systems, CAD/CAM systems, instruments, dental materials, implants, orthodontic products, and software and digital workflow solutions.

Want to see what other hedge funds are holding XRAY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DENTSPLY SIRONA Inc. (NASDAQ:XRAY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.